BIOADHESIVE POLYMER CONJUGATES WITH ANTICANCER ACTIVITY

母项目致力于生物粘合剂的开发， 用于治疗的生物可识别抗炎聚合物结合物 结肠病的症状。这一提议的FIRCA应用扩展了这些研究 生物粘附性、生物可识别性抗癌聚合物的开发 结合物用于治疗结直肠腺癌。这些 系统将基于N-(2-羟丙基)结合的概念 甲基丙烯酰胺(HPMA)-花生凝集素(PNA)-9- 氨基喜树碱(9-AC)通过特定的PNA结合到病变部位。 糖蛋白相互作用和位点特异性释放的概念 只在结肠中存在的微生物酶对9-AC的作用。其目的是为了 设计可直接靶向癌症组织的高效结合物。 该应用程序还建议研究 共聚物偶联物的结构及9-AC的体外和体内释放 活着。将同时使用大鼠和人体组织，并且相关性 动物和人类之间的数据将被建立。

The parent project is devoted to the development of bioadhesive, biorecognizable anti-inflammatory polymer conjugates for the treatment of colon disease. This proposed FIRCA application extends these studies into the development of bioadhesive, biorecognizable anticancer polymer conjugates for the treatment of colorectal adenocarcinoma. These systems will be based on the concept of binding of N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymer-peanut agglutinin (PNA)-9- aminocamptothecin (9-AC) conjugates to diseased sites by specific PNA- glycoprotein interactions, and on the concept of site-specific release of 9-AC by microbial enzymes present only in the colon. The aim is to design efficient conjugates targetable directly to the cancer tissue. The application also proposes to study the relationship between the structure of the copolymer conjugates and 9-AC release in vitro and in vivo. Both rat and human tissues will be used, and the correlation between animal and human data will be established.